Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 22;6(4):805–827. doi: 10.20517/cdr.2023.77

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023.

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

(A) Schematic illustration of the preparation of supramolecular nanoprodrugsDOX@GP5Pro-NFA and their applications in overcoming cancer drug resistance; (B) Cell viability of HepG2 cells and HepG2/ADR cells treated with free DOX and DOX@GP5Pro-NFA, respectively. This figure is quoted with permission from Yang et al.^[177]; (C) Schematic illustration of the preparation of supramolecular nanoprodrugs DOX@GP5Pro-ANI and their applications in overcoming cancer drug resistance; (D) Cell viability of HepG2/ADR cells treated with free DOX and DOX@GP5Pro-ANI (^**P < 0.01). This figure is quoted with permission from Yang et al.^[180]. DOX: Doxorubicin; GP5: galactose-modified pillar[5]arene.

Inline graphic — (A) Schematic illustration of the preparation of supramolecular nanoprodrugsDOX@GP5Pro-NFA and their applications in overcoming cancer drug resistance; (B) Cell viability of HepG2 cells and HepG2/ADR cells treated with free DOX and DOX@GP5Pro-NFA, respectively. This figure is quoted with permission from Yang et al.^[177]; (C) Schematic illustration of the preparation of supramolecular nanoprodrugs DOX@GP5Pro-ANI and their applications in overcoming cancer drug resistance; (D) Cell viability of HepG2/ADR cells treated with free DOX and DOX@GP5Pro-ANI (^**P < 0.01). This figure is quoted with permission from Yang et al.^[180]. DOX: Doxorubicin; GP5: galactose-modified pillar[5]arene.